FinnGen

FinnGen
Name	FinnGen
Type	Public–private biomedical research
Country	Finland
Established	2017
Participants	500,000+
Partners	Pharmaceutical companies, academic institutions, biobanks

FinnGen FinnGen is a large-scale Finnish biomedical research project combining genotype and health record data to study genetic determinants of disease. The project links national health registries, hospital records, and population-based biobanks to enable association studies related to common and rare disorders. It operates through collaborations among Finnish research institutions, pharmaceutical companies, and national biobank infrastructures.

Overview

The initiative integrates data from national resources such as Finnish Institute for Health and Welfare, National Institute for Health and Welfare (Finland), and regional hospital districts with contributions from partners like Novo Nordisk, Pfizer, GlaxoSmithKline, Sanofi, and AstraZeneca. Core institutional participants include University of Helsinki, Helsinki University Hospital, University of Turku, and the University of Oulu. The project utilizes national identifiers and electronic health records derived from registers such as the Care Register for Health Care and the Register of Primary Health Care Visits to perform genome-wide association studies and phenome-wide scans.

History and Governance

Planning began in the mid-2010s amid discussions in forums involving Sitra, the Ministry of Social Affairs and Health (Finland), and the Finnish Medicines Agency (Fimea). Formal launch occurred with coordination among Finnish biobanks like Auria Biobank, THL Biobank, Tampere Biobank, and Northern Finland Biobank Borealis. Governance structures involve steering groups with representatives from pharmaceutical partners, academic leaders from Karolinska Institutet collaborations, and national ethics oversight bodies such as regional ethics committees and the European Medicines Agency. Funding combines public sources, private contracts with companies including AbbVie and Bristol Myers Squibb, and institutional contributions from universities and hospitals.

Study Design and Methods

The project employs large-scale genotyping arrays and imputation panels built from whole-genome sequencing reference panels such as those used by the 1000 Genomes Project and national sequencing efforts. Analytical pipelines use tools and frameworks established in consortia like the Wellcome Trust Case Control Consortium and computational infrastructure from centers such as the CSC – IT Center for Science. Methods include genome-wide association studies, meta-analyses with datasets from UK Biobank and the Estonian Biobank, polygenic risk score derivation comparable to work by groups at Broad Institute and Massachusetts General Hospital, and fine-mapping approaches utilized by teams at Stanford University and University of California, San Francisco.

Participants and Recruitment

Recruitment channels include patients from specialist clinics at institutions like Tampere University Hospital, participants from population cohorts such as the FINRISK studies, and blood donors through collaborations with Finnish Red Cross Blood Service. Consent procedures were aligned with recommendations from bodies including the Council of Europe and involve protocols similar to those used by biobanks like the UK Biobank. Target enrollment aims to cover diverse Finnish regional populations represented across municipalities such as Helsinki, Turku, Oulu, and Tampere.

Data Types and Biobanks

Data modalities integrated consist of genotype arrays, imputed genotypes, whole-genome and whole-exome sequences, electronic health records, prescription registries like the Prescription Centre (Finland), and disease registries exemplified by the Cancer Registry of Finland. Participating biobanks include Finnish Clinical Biobank Tampere, Biobank of Eastern Finland, and clinical sample collections from Helsinki Biobank. Linkage to longitudinal registers such as the Causes of Death Register and socioeconomic databases maintained by agencies like Statistics Finland enables broad phenotype definition and covariate adjustment.

Research Findings and Publications

Analyses have identified associations relevant to cardiometabolic disease, immunological traits, oncology, and pharmacogenomics, drawing comparisons with findings from consortia like the Global Lipids Genetics Consortium and the International Stroke Genetics Consortium. Publications stemming from the project have appeared in journals where teams affiliated with University of Helsinki and collaborators at Harvard Medical School and University of Cambridge have reported novel loci, rare variant discoveries, and drug target validation studies. Collaborative meta-analyses have integrated FinnGen results with datasets from deCODE genetics and Icelandic Biobank-linked studies to refine effect estimates and translational hypotheses.

Ethical, Legal and Privacy Considerations

Ethical oversight involves review by Finnish regional ethics committees and aligns with legal frameworks such as the European Union regulations on data protection and guidance from the European Data Protection Supervisor. Consent models and data access policies mirror principles advanced by the OECD and intersect with debates in forums including the Nuffield Council on Bioethics. Data governance balances researcher access for institutions like Karolinska Institutet and industry partners with participant privacy safeguarded through pseudonymization, controlled-access procedures, and oversight by biobank governance boards exemplified by those at THL Biobank and other national repositories.

Category:Biobank projects